Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03331744
Other study ID # 2017-118
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date October 6, 2017
Est. completion date December 1, 2025

Study information

Verified date January 2024
Source West China Hospital
Contact Yi Ji
Phone +86 02885423453
Email jijiyuanyuan@163.com
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

The primary purpose of this study is to identify the clinical characteristics of infantile hemangioma (IH) in our single center in China. The second objective of the study is to identify the clinical features of infantile hepatic hemangioma (IHH) and ulceration in patients with IHs.


Description:

Infantile hemangioma (IH) is the most common benign tumor of infancy with an estimated prevalence of 4%-5%. IHs may be presented in any part of body including the visceral organs, but are preferentially located on the face, head and neck area. IHs exhibit a characteristic life cycle consisting of a rapid proliferating phase within the first year of life followed by a slowly involuted phase lasting for up to five years. Although most resolve over time without major sequelae, a significant subset can result in severe complications including disfiguring and ulceration, some even could impair organ functions and threaten patients' life. Risk factors of IHs have been identified including multiple gestation, low birth weight, prematurity, white race, eclampsia and placental abnormalities. However, the exact occurrence, clinical features and risk factors of IHs is still unknown in Chinese patients because of the lack of large scale of prospective studies. In addition, characteristics of ulceration of IHs and infantile hepatic hemangiomas (IHHs) are also not well documented. Therefore, it's important to perform this prospective study to determine the clinical features of Chinese patients with IHs, and this study will also make contributions to the prevents, diagnoses and treatments of IHs.


Recruitment information / eligibility

Status Recruiting
Enrollment 1000
Est. completion date December 1, 2025
Est. primary completion date December 1, 2025
Accepts healthy volunteers
Gender All
Age group N/A to 6 Years
Eligibility Inclusion Criteria: - Age =6 years old - Diagnose of IHs - Consent of both parents (or the person having parental authority in families) Exclusion Criteria: - Congenital hemangioma, kaposiform hemangioendothelioma, or other vascular anomalies - Age>6 years - Hemangioma has been previous treated with corticosteroids, laser, cryotherapy, or only other treatments - Patients with an inability to participate or to follow the study treatment and assessment plan

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
China West China Hospital of Sichuan University Chengdu Sichuan

Sponsors (1)

Lead Sponsor Collaborator
West China Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Location, size, phase of growth, morphologic subtypes, complication and outcome of IHs in patients. Clinical characteristics of infantile hemangioma. Phase of growth include proliferation, plateau and involution phase. Morphologic subtypes include localized, segmental, indeterminate and multifocal type. 2 years
Secondary Demographic information of IH about patient gender, birth weight, race, gestational age, prenatal testing procedures, placental abnormalities, maternal complications during pregnancy, type of fertilization and delivery type are collected. Demographic characteristics in patients with IH. 2 years
Secondary Demographic information of IHH about patient gender, birth weight, race, gestational age, prenatal testing procedures, placental abnormalities, maternal complications during pregnancy, type of fertilization and delivery type are collected. Demographic characteristics in patients with infantile hepatic hemangioma. 2 years
Secondary Size, type of lesion (focal, multiple and diffuse), complication and outcome of infantile hepatic hemangioma. Clinical characteristics of infantile hepatic hemangioma 2 years
Secondary Location, size, complication and outcome in patients with ulcerated IHs. Clinical characteristics of ulcerated IHs. Phase of growth include proliferation, plateau and involution, and morphologic subtypes include localized, segmental, indeterminate and multifocal type. 2 years
See also
  Status Clinical Trial Phase
Completed NCT01685398 - Topical Timolol for Superficial Infantile Hemangioma Phase 3
Withdrawn NCT00974129 - A Study of CCCTC-binding Factor (CTCF) in Infantile Hemangiomas N/A
Completed NCT00374335 - Incidence of Hepatic Hemangiomatosis in Patients With Cutaneous Hemangiomas N/A
Completed NCT02342275 - Efficacy and Safety of Propranolol Versus Atenolol on the Proliferative Phase of Infantile Hemangioma Phase 3
Completed NCT00433940 - Immune Suppression Of Infants Treated With Steroids N/A
Completed NCT04065217 - The Effectiveness of Diode Laser 980-nm in Iraqi Face Hemangioma: a Randomized Within Patients Trial N/A
Terminated NCT01743885 - Efficacy and Safety of Propranolol Versus Acebutolol on the Proliferative Phase of Infantile Hemangioma Phase 3
Terminated NCT00555464 - Clinical Trial of Vincristine vs. Prednisolone for Treatment of Complicated Hemangiomas Phase 2
Completed NCT00394888 - Hemangioma Associated With High Rates of Morbidity N/A
Completed NCT05327309 - Role of Propranolol as Compared to Bleomycin in Management of Hemangioma N/A
Completed NCT02145884 - Topical Timolol Gel for the Treatment of Infantile Hemangiomas Phase 2
Completed NCT04077515 - Safety and Efficacy of Low-dose Sirolimus to Kaposiform Hemangioendothelioma Phase 4
Completed NCT02731287 - Topical Timolol for Infantile Hemangioma in Early Proliferative Phase Phase 2
Recruiting NCT01147601 - Topical Timolol 0.5% Solution for Proliferating Infantile Hemangiomas Phase 0
Completed NCT01908972 - The Safety and Efficiency of Propranolol as an Initial Treatment for Pediatric Hemangioma Phase 4
Completed NCT00540566 - Optical Biopsy of Human Skin in Conjunction With Laser Treatment
Completed NCT00001417 - Direct Injection of Alcohol for the Treatment of Spinal Tumors N/A
Completed NCT00004436 - Randomized Study of Hormonal Regulation of Infantile Hemangioma N/A
Recruiting NCT02496013 - Clinical Translation of a Novel Albumin-Binding PET Radiotracer 68Ga-NEB Phase 1
Completed NCT01072045 - Comparative Study of the Use of Beta Blocker and Oral Corticosteroid in the Treatment of Infantile Hemangioma Phase 2